Your browser doesn't support javascript.
loading
Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial.
Inoue, Nagamu; Kobayashi, Kiyonori; Naganuma, Makoto; Hirai, Fumihito; Ozawa, Morio; Arikan, Dilek; Huang, Bidan; Robinson, Anne M; Thakkar, Roopal B; Hibi, Toshifumi.
Affiliation
  • Inoue N; Center for Preventive Medicine, Keio University Hospital, Tokyo, Japan.
  • Kobayashi K; Department of Gastroenterology, Kitasato University Hospital, Kanagawa, Japan.
  • Naganuma M; Division of Gastroenterology & Hepatology, Department of Internal Medicine, Keio University School of Medicine, Fukuoka, Japan.
  • Hirai F; IBD Center, Fukuoka University Chikushi Hospital, Fukuoka, Japan.
  • Ozawa M; AbbVie GK, Tokyo, Japan.
  • Arikan D; AbbVie Inc., North Chicago, IL, USA.
  • Huang B; AbbVie Inc., North Chicago, IL, USA.
  • Robinson AM; AbbVie Inc., North Chicago, IL, USA.
  • Thakkar RB; AbbVie Inc., North Chicago, IL, USA.
  • Hibi T; Center for Advanced IBD Research and Treatment, Kitasato Institute Hospital, Kitasato University, Tokyo, Japan.
Intest Res ; 15(3): 395-401, 2017 Jul.
Article in En | MEDLINE | ID: mdl-28670237
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Intest Res Year: 2017 Document type: Article Affiliation country: Japan Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Intest Res Year: 2017 Document type: Article Affiliation country: Japan Country of publication: